Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 15/20 | 0.74 |
| ▸ | BCHE | P06276 | 10/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18065461 | 0.98 | ACHE (0.73) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL2124292 | 0.97 | ACHE (0.74) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL4266767 | 0.90 | ACHE (0.74) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL29817918 | 0.84 | BCHE (0.79) | ACHEBCHEMAPTSLC2A1 | |
| SCHEMBL29023217 | 0.84 | ACHE (0.73) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL30356238 | 0.84 | ACHE (0.73) | ACHEBCHEGRIN1GRIN2AMAPT | |
| Hydrochloric Acid SCHEMBL29817833 | 0.84 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2ACHRM1 | |
| SCHEMBL29818075 | 0.83 | BCHE (0.77) | ACHEBCHEMAPTSLC2A1 | |
| SCHEMBL30991441 | 0.83 | ACHE (0.70) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL1337681 | 0.83 | ACHE (0.70) | ACHEBCHEGRIN1GRIN2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071558-A1 | NOVEL UNCHARGED REACTIVATORS AGAINST OP-INHIBITION OF HUMAN ACETYLCHOLINESTERASE | Université de Strasbourg (FR) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272620-A1 | NOVEL UNCHARGED REACTIVATORS AGAINST OP-INHIBITION OF HUMAN ACETYLCHOLINESTERASE | UNIV STRASBOURG (FR) | 2016-09-22 | — | — | US | disclosed |
| US-20160272620-A1 | NOVEL UNCHARGED REACTIVATORS AGAINST OP-INHIBITION OF HUMAN ACETYLCHOLINESTERASE | UNIV STRASBOURG (FR) | 2016-09-22 | — | — | US | disclosed |
| WO-2015075082-A1 | NOVEL UNCHARGED REACTIVATORS AGAINST OP-INHIBITION OF HUMAN ACETYLCHOLINESTERASE | UNIVERSITE DE STRASBOURG (FR) | 2015-05-28 | — | — | WO | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272620-A1 | NOVEL UNCHARGED REACTIVATORS AGAINST OP-INHIBITION OF HUMAN ACETYLCHOLINESTERASE | ACHE, BCHE, CHAT | ACHE 1/4885BCHE 2/4885GRIN1 298/4885 |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ACHE 3061/4885BCHE 1616/4885GRIN1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.